Close Menu

Fermentas

US patents awarded to University of California, Hospital for Sick Children, Thermo Fisher, Fujifilm, Abbott, and Novartis.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

When considering Thermo's planned acquisition of molecular biology tool shop Fermentas, its acquisition earlier this year of Finnish PCR firm Finnzymes, and recent product launches, it appears as if the company plans to make a run at disease diagnostics, food testing, and other PCR-based testing markets.

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Based in Ontario with principal operations in Lithuania, Fermentas offers reagents for nucleic acid and protein purification, restriction and modifying enzymes, and various PCR products.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.